Phathom Pharmaceuticals Q3 Revenue Jumps 71%; Reaffirms FY26 Outlook
Phathom Pharmaceuticals (PHAT) reported Q3 2026 net revenue of $84.7M, up 71% YoY, driven by VOQUEZNA prescriptions. Net loss narrowed to $13.9M. The company reaffirmed FY26 guidance of $310M-$325M in revenue. VOQUEZNA prescriptions exceeded 2M through October 2026, with 380K in Q3.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance reaffirmation provide a fresh catalyst that could attract short‑term buying pressure.
Market read
First‑report earnings and guidance for a micro‑cap biotech; potential modest price move.
What to watch
Future Phase 3 results and potential competition could temper upside.
Background
Phathom Pharmaceuticals reported Q3 results with a 71% revenue increase and reaffirmed FY26 guidance.
Ticker impact
Q3 2026 revenue jumped 71% to $84.7M and the company reaffirmed FY26 guidance, providing fresh earnings data.
likely modest upside as market prices in the revenue beat and guidance reaffirmation
Revenue growth and narrowed loss signal improving fundamentals; no new risks disclosed.
Market effects
Strengthens outlook for the gastro‑esophageal reflux disease therapeutic niche.
U.S. biotech sector may see slight uplift.
Limited to investors tracking small‑cap pharma earnings.
Counterpoint
Revenue growth may be unsustainable; cash burn remains high.
Key entities
- CompanyPhathom Pharmaceuticals, Inc.
Biopharmaceutical company developing VOQUEZNA for GERD.



